Imugene (IMU) H2 2024 earnings summary

Executive summary

• Achieved significant progress in clinical pipeline, including acquisition of azer-cel CAR T cell therapy and strategic partnership with Kincell Bio, saving ~$49 million in manufacturing costs.

• Raised $35 million via placement and $18.2 million through a share purchase plan to fund acquisitions and clinical trials.

• Expanded management team with key hires in COO, CMO, and SVP Clinical Development roles.

Financial highlights

• Reported net loss of $149.7 million for FY24, up from $37.9 million in FY23, mainly due to increased R&D and clinical trial activity.

• Cash reserves at 30 June 2024 were $93.1 million, down from $153.2 million a year earlier.

• Net assets decreased to $118.3 million from $189.6 million year-over-year.

• No dividends declared or paid for FY24.

Outlook and guidance

• Early data from azer-cel Phase 1b trial expected in H2 2024; registrational study planned.

• VAXINIA and onCARlytics trials progressing, with expansion into new cohorts and geographies.

• No short- or medium-term revenue expected; focus remains on advancing clinical programs.